MedPath

Clinical Trial News

NCCN Updates Prostate Cancer Guidelines: Stratified Treatment for Metastatic Hormone-Sensitive Disease

  • The 2024 NCCN guidelines for metastatic hormone-sensitive prostate cancer (mHSPC) now stratify treatment recommendations based on disease volume and timing of metastases.
  • Triplet therapy (ADT, docetaxel, and either abiraterone or darolutamide) is recommended for high-volume synchronous mHSPC, based on ARASENS and PEACE-1 trial data.
  • For low-volume synchronous or high-volume metachronous mHSPC, doublet therapy (ADT plus an androgen receptor pathway inhibitor) is preferred, with consideration of prostate radiotherapy in select cases.
  • SBRT is recognized as an expanding option for oligometastatic progression, with ongoing trials exploring its role in various mHSPC settings.

Viking Therapeutics Advances Weight Loss and Metabolic Disease Programs

  • Viking Therapeutics is progressing VK2735, a dual GLP-1/GIP agonist, into Phase 3 trials for obesity, with an end-of-Phase 2 meeting with the FDA expected by year-end.
  • Oral formulation of VK2735 demonstrated encouraging Phase 1 results, with Phase 2 trials anticipated to begin in the final quarter of the year, offering a potentially more appealing treatment option.
  • VK2809, targeting non-alcoholic steatohepatitis (NASH), met primary and secondary endpoints in a Phase 2b trial, showcasing Viking's broader focus on metabolic disorders.
  • Analysts are optimistic about Viking's potential, with JPMorgan initiating coverage with an "Overweight" rating and anticipating positive data from oral VK2735 at Obesity Week.

JAK Inhibitor Safety Profiles Show Age-Related Differences in Pediatric vs. Adult Patients

  • A recent study analyzing FDA adverse event reports reveals differences in adverse event (AE) profiles between pediatric and adult patients treated with JAK inhibitors.
  • Adult patients reported more AEs related to infections, general symptoms, musculoskeletal, gastrointestinal, and nervous system disorders.
  • Pediatric patients experienced a higher incidence of blood and lymphatic system disorders, infections, and gastrointestinal issues.
  • The study suggests that while JAK inhibitors are generally safe, age-related differences in AE profiles should be considered in clinical practice.

Neffy Pre-Orders Launch, Trofinetide Data Highlighted, and Screen Time Impact on Sleep Assessed

  • Pre-ordering has commenced for Neffy, an epinephrine nasal spray, offering a needle-free option for treating anaphylaxis in adults and children.
  • Trofinetide (Daybue) shows promise in treating Rett syndrome, with studies confirming its efficacy and safety in improving behavioral symptoms.
  • A study indicates that not all screen time before bed negatively impacts sleep in children, suggesting a need for revised recommendations.
  • Research suggests that fish intake during pregnancy is associated with a reduced likelihood of autism diagnosis in children.

Psychedelics Show Promise in Clinical Settings but Require Enhanced Safety Monitoring

  • A systematic review and meta-analysis of 114 studies indicates that classic psychedelics like LSD and psilocybin are generally well-tolerated in monitored clinical settings.
  • Serious adverse events were rare, with approximately 4% of participants with neuropsychiatric disorders experiencing SAEs, such as worsening depression or psychosis.
  • The study highlights significant gaps in adverse event reporting, emphasizing the need for improved pharmacovigilance practices to accurately assess risks and benefits.
  • Findings suggest a safer profile in clinical settings compared to recreational use, where catastrophic events like persistent psychotic disorders are more frequently reported.

Bioxcel Therapeutics Gains Analyst Confidence with Agitation Treatment Advancements

  • H.C. Wainwright reiterated a Buy rating for Bioxcel Therapeutics (BTAI), citing the Phase 3 trial of BXCL501 for agitation in bipolar disorder and schizophrenia.
  • The SERENITY At-Home trial's progress and potential for top-line results in H2 2025 could significantly increase the company's value.
  • Positive outcomes from the IGALMI post-marketing study, showing no tachyphylaxis, tolerance, or withdrawal, further support the Buy rating.
  • FDA's positive review of the SERENITY trial and planned submission of the TRANQUILITY trial for Alzheimer's agitation are viewed as positive steps.

Qualigen Therapeutics Announces Public Offering to Advance Cancer Programs

  • Qualigen Therapeutics is offering 14.7 million shares of common stock at $0.13 per share to fund operations and cancer drug development.
  • The offering includes pre-funded warrants for certain purchasers and aims to raise approximately $3.1 million after deducting fees.
  • Proceeds will support the clinical trial of QN-302 for pancreatic cancer and preclinical studies of the Pan-RAS program.
  • The offering's closing is expected by September 9, 2024, with Univest Securities, LLC acting as the exclusive placement agent.

FDA Meeting Highlights Urgent Need for Innovative PTSD Therapies, Including MDMA-Assisted Therapy

  • The FDA and Reagan-Udall Foundation convened a meeting to discuss advancing treatments for Post-Traumatic Stress Disorder (PTSD), highlighting the urgent need for innovative therapies.
  • Stakeholders, including individuals with PTSD and experts, voiced their support for MDMA-assisted therapy, despite the FDA's recent rejection of its application.
  • Experts emphasized MDMA-assisted therapy's potential to enhance neuroplasticity and allow patients to revisit traumatic experiences in a safe environment, fostering healing.
  • The meeting underscored the importance of addressing racial trauma and utilizing holistic tools to evaluate healing, particularly for communities of color.

Managing Toxicities in CLL Treatment: Expert Insights on BCL2 and BTK Inhibitor Selection

  • Leading experts at SOHO 2024 discuss critical strategies for managing toxicities in chronic lymphocytic leukemia patients treated with BCL2 and BTK inhibitors, emphasizing patient-specific approaches.
  • Renal function monitoring for BCL2 inhibitors and cardiovascular risk assessment for BTK inhibitors emerge as key considerations in treatment selection, with specific attention to comorbidities.
  • Novel treatment approaches including combination therapies, along with lifestyle interventions through programs like Health for CLL, are showing promise in improving patient outcomes and quality of life.

Collaborative Care Model Shows Strong Improvement in Depression and Anxiety Symptoms

  • A Kaiser Permanente study reveals that both collaborative care and traditional psychiatric treatment significantly improve depression and anxiety symptoms.
  • Collaborative care patients experienced a more substantial improvement, with depression symptoms decreasing by an average of 9 points.
  • A high proportion of depression patients in both programs achieved full remission, with 43% in collaborative care compared to 27% in specialty care.
  • The collaborative care model integrates frequent symptom monitoring, personalized treatment, and support from therapists and pharmacists.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy